Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) in Routine Clinical Practice

Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated CLL patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%) patients we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Finnes, Heidi D., Chaffee, Kari G., Call, Timothy G., Ding, Wei, Kenderian, Saad S., Bowen, Deborah A., Conte, Michael, McCullough, Kristen B., Merten, Julianna A., Bartoo, Gabriel T., Smith, Matthew D., Leis, Jose, Chanan-Khan, Asher, Schwager, Susan M., Slager, Susan L., Kay, Neil E., Shanafelt, Tait D., Parikh, Sameer A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5364094/
https://ncbi.nlm.nih.gov/pubmed/27820970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1251592
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados